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Abstract 
T-type Ca2+ channels (TTCC) have been identified as key regulators of cancer cell cycle and survival. In vivo 
studies in glioblastoma (GBM) murine xenografts have shown that drugs able to block TTCC in vitro (such as 
tetralol derivatives mibefradil/NNC-55-096, or different 3,4-dihydroquinazolines) slow tumor progression. 
However, currently available TTCC pharmacological blockers have limited selectivity for TTCC, and are unable to 
distinguish between TTCC isoforms. Here we analyzed the expression of TTCC transcripts in human GBM cells 
and show a prevalence of Cav3.1 mRNAs. Infection of GBM cells with lentiviral particles carrying shRNA against 
Cav3.1 resulted in GBM cell death by apoptosis. We generated a murine GBM xenograft via subcutaneous 
injection of U87-MG GBM cells and found that tumor size was reduced when Cav3.1 expression was silenced. 
Furthermore, we developed an in vitro model of temozolomide-resistant GBM that showed increased 
expression of Cav3.1 accompanied by activation of macroautophagy. We confirmed a positive correlation 
between Cav3.1 and autophagic markers in both GBM cultures and biopsies. Of note, Cav3.1 knockdown resulted 
in transcriptional downregulation of p62/SQSTM1 and deficient autophagy. Together, these data identify Cav3.1 
channels as potential targets for slowing GBM progression and recurrence based on their role in regulating 
autophagy. 
 
Statement of significance: Findings identify Cav3.1 calcium channels as a molecular target to regulate autophagy 
and prevent progression and chemotherapeutic resistance in glioblastoma   
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Highlights: 
• Glioblastoma is a brain tumor of fatal prognosis, for which recurrence is very high, in part due to 
therapeutic resistance cellular mechanisms. 
• T-type calcium channel Cav3.1 is predominantly expressed in glioblastoma (GBM) and upregulated in 
recurrent/resistant GBM 
• Autophagy is a cellular strategy that promotes survival of cancer cells, exacerbated upon chemotherapy.  
• Depleting Cav3.1 promotes glioblastoma cell death and alters autophagy. 
• In vivo results suggest a key role of Cav3.1 controlling the growth of GBM.  
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INTRODUCTION 
Gliomas are primary brain tumors classified by the World Health Organization as diffuse astrocytoma 
(grade II), anaplastic astrocytoma (grade III) and glioblastoma multiforme (GBM; grade IV)(1)(2). GBMs are 
the most common and aggressive gliomas, implying a lethal prognosis (3). GBM features include high cell 
proliferation and invasion capacities, apoptosis resistance, necrosis and angiogenesis (4). Despite extensive 
surgery, radiotherapy and chemotherapy with temozolomide (TMZ), GBM recurrence is unfortunately very 
common. Moreover, TMZ triggers pro-adaptive cellular responses such as autophagy (5).  
Ca2+ is a ubiquitous second messenger that integrates multiple signal transduction pathways relevant for 
cell biology (reviewed in (6)). Cancer cells frequently experience a remodeling of the Ca2+ signaling 
pathways that facilitates cell proliferation and survival (7). Among them, T-type Ca2+ channels (TTCC) are 
often aberrantly expressed in different tumors, including over and under expression when compared to 
untransformed tissues (reviewed by (8)).  
TTCCs consist of three highly homologous isoforms, Cav3.1, Cav3.2 and Cav3.3, that display only ~25% amino 
acid sequence identity compared to other voltage-gated Ca2+ channels (9). TTCC activate at negative 
membrane potentials, in which  there is a high driving force for Ca2+ entry, and display slow deactivation 
kinetics (10). By virtue of these distinctive properties, TTCC provide a key pathway for Ca2+ entry near the 
resting membrane potential. The expression of TTCC is linked to the cell cycle, increasing during the G1-S 
transition (11)(12)(13). A number of reports associate the expression of Cav3.1 and Cav3.2 to the 
proliferation of cancer cells in vitro (14)(15)(16)(17). Particularly, the role of TTCC in GBM progression has 
received considerable attention in recent years. Thus, the effects of pharmacological blockers on halting 
proliferation and inducing apoptosis of GBM cells in vitro led to the development of murine GBM 
xenografts, in which TTCC pharmacological blockers reduced tumor growth (18)(19)(20). Although currently 
available blockers cannot discriminate between TTCC isoforms and are also reported to exert off-target 
actions, some authors have linked TTCC isoform detection with drug effects in what it can be considered as 
a loose target identification. However, the distinction between TTCC isoforms is relevant, since they are 
associated to different signaling pathways and play different physiological roles (reviewed by (8)). 
Recently, Zhang et al. have shown that the Cav3.2 isoform is highly expressed in GBM stem cells (GSC) (20) 
In this study, treatment with the TTCC blocker mibefradil downregulated GSC proliferation and stemness 
markers, and the authors concluded that Cav3.2 is involved in the maintenance of undifferentiated stem 
cells, in agreement with (21). However, Niklasson et al. found the expression of both Cav3.1 and Cav3.2 in 
GSC (22). In fact, Cav3.1 appears to be the prevalent TTCC isoform in GBM: according to the Human Protein 
Atlas, 82% of biopsies expressed Cav3.1 and 27% expressed Cav3.2 (23).  
We have previously identified a positive relationship between Cav3.1 expression and autophagy markers in 
melanoma biopsies (24). Here we set out to investigate the effects of knocking down Cav3.1 in cultured 
GBM cells and in a murine xenograft model of GBM. In addition, we studied TTCC expression and the 
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autophagic status in a model of TMZ-resistant GBM, because the induction of macroautophagy (hereafter, 
autophagy) is a cellular strategy for chemotherapeutic resistance. Our results show that gene silencing of  
Cav3.1 dramatically reduces the viability of GBM cells and slows tumor progression. In addition, Cav3.1 
positively correlates with autophagy markers P62/SQSTM1 and LC3 in GBM, while depletion of Cav3.1 
reduces P62 levels. Together, our results pinpoint Cav3.1 channels as molecular targets for tackling GBM 
growth and recurrence through autophagy deregulation. 
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MATERIALS AND METHODS  
Reagents and antibodies 
Biochemical reagents were from the following companies: temozolomide (TMZ; T2577), rapamycin (R8781), 
puromycin (P7255), chloroquine (C6628) and mibefradil (M5441) from Sigma-Aldrich; bafilomycin-A (sc-201550) 
and NNC-55-0396 (sc-203647) from Santa Cruz Biotechnology. Antibodies used were: CyclinD1/CCND1 (BD 
Biosciences, 556470), BECLIN1 (Novus Biologicals, NB110-87318), MAP1LC3A/B (Novus Biologicals, NB100-
2331), β-actin/ACTB (Sigma-Aldrich, A5441), P62/SQSTM1 (Novus Biologicals, NBP1- 48320) and ATG5 (Sigma-
Aldrich, A2859), P-AMPK (Thr172; Biorbyt, orb127615) and Ubiquitin (Santa Cruz Biotechnology, sc-8017).  
 
Cell culture and biopsies 
GBM cell lines A172, U251-MG and U87-MG were obtained from ATCC. Cells were maintained in Minimal 
Essential Medium (Lonza, BE12-125F) containing 10% Fetal Bovine Serum (FBS; Gibco, 10270098), 
penicillin/streptomycin (Gibco, 15140-122), L-glutamine (Gibco, 25030-081), 1% amino acids (Gibco, 11140-035) 
and 1% sodium pyruvate (Gibco, 11360-039) at 37°C and 5% CO2 atmosphere. All cell lines were authenticated 
by short tandem repeat profiling (Stab Vida, Portugal) following purification of genomic DNA using the 
Maxwell16 Tissue DNA kit (Promega, AS1030). RC1 and RC2 TMZ-resistant cells were obtained from the A172 
cell line by exposure to increasing concentrations of TMZ over several weeks. Resistant cells were cultured in 
complete media plus 200 µM TMZ. Both RC1 and RC2 were authenticated as A172 cells (Stab Vida, Portugal). 
Cells lines were grown in mycoplasma-free rooms and mycoplasma testing was performed by PCR on parental 
A172, U87-MG and U251-MG cells. Cells that tested positive were either discarded or treated with Plasmocin 
(Invivogen, ant-mpt-1). Cell lines were passaged for 20-25 passages.   
Neurosphere (NS) cultures were grown from adherent U87-MG cells in suspension in Neurobasal media (Gibco 
LS21103049) containing B27 Supplement (1:50; Gibco 17504044), penicillin/streptomycin and L-glutamine, 20 
ng/ml bFGF (Gibco, 13256029) and 20 ng/ml EGF (Gibco, PHG0314) for 7 days. Growth factors were refreshed 
after 3 days. 
Paired samples of primary and recurrent GBM from the same patient were obtained through the Biobank 
Network-Carlos III Health Institute (NavarraBiomed, Toledo and Basque Biobanks). Studies were conducted in 
accordance with the Law of Biomedical Research 14/2007 and the guidelines of Declaration of Helsinki. Written 
informed consents from patients were obtained as part of the Biobancos Network (Carlos III Health Institute, 
Spain) standard operating procedures. The study was approved by the review board of the different Biobank 
involved and by the Ethical Committee of our university. Frozen OCT sections of 15 µm were used to extract 
RNAs using Maxwell 16 LEV simplyRNA kit (Promega, AS1270). Most patients followed standard treatment 
consisting of radiotherapy and TMZ before recurrence, except for P1 who refused it (treatment information for 
P3 was not available).   
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Conventional cytogenetics  
Dividing cells were arrested in metaphase by addition of Colcemid (Gibco 15212012; 90 min, 37°C). Cells were 
then trypsinized and sedimented before treatment with a hypotonic solution. The nuclei were fixed with Carnoy 
and stained with Wright-Giemsa. Chromosomes from 4-10 metaphases were studied.  
 
Cell transfection  
GBM cells were plated the day before transfection at 80% of confluency. Transfection of tandem fluorescent-
tagged LC3A (ptfLC3) plasmid using Lipofectamine-2000 (Invitrogen, 11668-027) was as described (25). The 
ptfLC3 plasmid, a kind gift from Dr. T. Yoshimori (University of Osaka, Japan)(26) is a LC3A tandem flagged 
construct that codifies for green fluorescent protein pEGFP-LC3A and red fluorescent protein mRFP-LC3A. After 
24h of transfection, cells were treated with 25 µM chloroquine or 500 nM rapamycin for 24h. At 48h, cells were 
pictured under an epifluorescence microscope and analyzed for co-localization of green and red puncta. 
Micrographs were obtained using an inverted Olympus IX70 microscope equipped with epifluorescence optics 
and a camera (Olympus OM-4 Ti) and images acquired using DPM Manager Software . Quantification of red and 
green puncta was performed using ImageJ software and pictures obtained from the EGFP and mRFP channels 
(about 30 cells were counted/condition from 3 independent experiments). Autophagy blockade is visualized by 
similar numbers of red and green puncta. In contrast, autophagy induction involves the predominance of red 
puncta (reflecting an increase of autolysosomes). 
 
Western blot 
Cells were washed with PBS and lysed in Tris 62.5 mM pH 6.8 and 2 % SDS. Cell lysates were resolved in SDS-
PAGE gels and transferred to a PVDF membrane (Merck-Millipore, IPVH00010). Membranes were cut to probe 
different antibodies on the same membrane. Membranes were blocked with 5% bovine serum albumin (Fisher 
Scientific, BP9701-100) or milk and incubated overnight with primary antibodies. Blots were developed using 
Enhanced Chemiluminiscence (ECL; Thermo Scientific, 32106) or Luminata Forte horseradish peroxidase 
substrate (Merck-Millipore, WBLUF0100).  
 
shRNA-induced gene silencing by lentiviral infection 
Lentiviral-based vectors for RNA interference-mediated gene silencing were pLKO.1-puro, containing shRNAs 
scrambled (against the sequence 5’ CAACAAGATGAAGAGCACCAA 3’), of Cav3.1#1 (Mission-RNA, Sigma-Aldrich; 
TRCN0000044239), Cav3.1#2 (TRCN0000430515), Cav3.2#1 (TRCN0000044209) and Cav3.2#2 
(TRCN0000044210). Lentiviral particles were produced in HEK293T (human embryonic kidney) cells for 72h upon 
transfection of the shRNA vectors together with psPAX2 and pMD2G plasmids using polyethylenimine. Medium 
was then centrifuged (2500 rpm) and filtered through 0.45 µm. Cells were incubated with medium containing 
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lentiviral particles together with polybrene (1.75 g/ml) for 24h. Medium was replaced to allow the knockdown 
for four or more days. As pLKO.1-puro vectors contain a puromycin resistance site, puromycin (4 µg/ml) was 
added to media to select for resistant cells. Silencing was assessed at day 4 after infection. For NS experiments, 
adherent cells infected with lentiviral particles on the previous day were grown in suspension as NS for 6 days in 
the presence of puromycin (refreshed after 3 days). Trypan Blue (0.2%) staining was performed on the 7th day of 
infection.  
 
Real time PCR 
RNA was isolated using a Nucleospin RNA isolation kit (Macherey-Nagel, 74095550). 1 µg of RNA was reverse 
transcribed (25 °C for 10 min, 42 °C for 1h and 95 °C for 5 min) using Superscript II reverse transcriptase (Applied 
Biosystems, 4308228). cDNA was then analyzed by quantitative PCR (qPCR; ABI Prism 7000HT, Applied 
Biosystems) using TaqMan hydrolysis probes labeled with FAM. Gene-specific probes for human Cav3.1 
(Hs00367969_m1), Cav3.2 (Hs00234934_m1), P62/SQSTM1 (Hs00177654_m1), CD133 (Hs01009259_m1) and 
GAPDH (used as internal control, Hs99999905_m1) were from Applied Biosystems. Samples were assayed in 
triplicate for each gene and relative expression calculated by the ΔΔCT method (Applied Biosystems).  
 
Cell viability assay  
Cell viability was measured by the WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5- tetrazolium]-1,3-benzene 
disulfonate; Roche, 05015944001) colorimetric assay. Cells were plated on 96-well plates (5000 cells/well), 
treated for 24h and then incubated for 60–120 min with 0.5 mg⁄ml WST-1 after 48h of plating. Absorbance was 
measured at 440 nm using a reference filter at 620 nm wavelength in a microplate reader (Bio-Rad 
Laboratories). Viability assays were performed in at least three independent experiments, using triplicate 
measurements per condition. 
 
Clonogenic assays 
For clonogenic assays, 500 cells/well were plated in 6-well plates. Cells were incubated for 12-15 days and 
stained with MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide, 0.5 mg/ml; Sigma, M2128).  
 
Apoptosis analysis 
For Annexin V/PI staining, cells were trypsinized, washed in PBS and centrifuged. In the case of TTCC blockers, 
experiments were performed after 24h of treatment. Annexin experiments using shRNA-mediated silencing 
were performed at 4 days (as controls) or at 6-7 of lentiviral infection. Cells were stained (15 min, RT) with 
Annexin V-FITC (Immunotools, 31490013) and PI (0.02 mg/ml; Sigma, P4170). The % of apoptotic cells was 
evaluated using FACSCanto II flow cytometer (BD Biosciences). 100000 cells were recorded per condition in 
three independent experiments. 
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Xenografts 
Severe Combined Immunodeficient (SCID) mice (male 12 week old; 20-25 g; maintained in Specific Pathogen 
Free conditions in the Animal House, UdL-IRBLleida) were subcutaneously injected with Cav3.1-deficient or 
control (scrambled shRNA) U87-MG cells (3x106 cells) suspended in 50 µl of PBS. All animal care and 
experimental procedures were performed in accordance with the EU Directive 2010/63/EU guidelines for animal 
experiments and approved by the Animal Ethics Committee at the University of Lleida (CEEA 06-05/16). The 
study complies with the ARRIVE guidelines developed by the NC3Rs (27). Tumors were allowed to grow for 13 
days and measured every two days using a caliper. Tumor size was calculated using the formula: tumor weight 
(mg) = (Dxd2)/2= mm3. Nine (six male and three female) animals were analyzed.  
 
Tissue microarray and immunohistochemistry  
A tissue microarray (TMA) (25) including 57 samples of formalin fixed and paraffin embedded GBMs was used. 
Samples were obtained with support by IRBLleida-Biobank (B.0000682) and Biobancos Platform 
(PT13/0010/0014). 
Paraffin blocks of xenograft tumors or human biopsies were sectioned and slides prepared for 
immunohistochemistry. The procedure of deparaffinization, rehydration, epitope retrieval, and staining was 
performed as described (25). The primary antibodies used were against P62 (1:3000 dilution), LC3A (1:100 
dilution), Cav3.1 (24), MKI67 (Ready to Use; DAKO, IR626) and CyclinD1 (Ready to Use; DAKO, IR083). 
Immunoexpression was graded by considering the % and intensity of the staining using an automated imaging 
system ACIS III Instrument (DAKO, Denmark). For P62 immunostaining quantification, cells showing strong 
immunopositity were counted. 
For the relationship among biomarkers in the TMA biopsies, a histological score was obtained for each sample, 
ranging from 0 (no immunoreaction) to 300 (maximum immunoreactivity)(24)(25). Pearson’s correlation tests 
were performed to establish significant relationships. 
 
Bioinformatics and statistical analysis 
TCGA data analysis: differential expression of CACNA1G (Cav3.1) and CACNA1G (Cav3.2) and its correlation with 
Overall Survival Kaplan Meier Estimates were assessed using the cBioportal platform (www.cBioportal.org)(28).  
For analysis of expression, the z-score (defined as z = (expression in tumor sample - mean expression in 
reference sample) / standard deviation of expression in reference sample) was set at ±1.  
Correlations between mRNA expression of Cav3.1/CACNA1G and P62/SQSTM1 or LC3/MAP1LC3 were analyzed 
in 217 GBM samples of the REMBRANDT dataset through the GlioVis portal (http://gliovis.bioinfo.cnio.es)(29).  
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All experiments are represented as mean ± s.e.m (n≥3 unless otherwise indicated). Student’s t-test was 
performed except otherwise indicated (*p<0.05; ** p<0.01; ***p< 0.001). 
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RESULTS   
GBM cells express Cav3.1 and Cav3.2, being Cav3.1 predominant.  
Zhang and colleagues recently reported that the Cav3.2 TTCC isoform is highly expressed in GSC, human GBM 
cell lines and specimens. The authors also performed an in silico genomic analysis of TCGA data that revealed 
overexpression of Cav3.2 in 13/136 GBM samples, and that these cases presented a trend towards shorter 
survival (20). Here we analyzed the TCGA database with identical z-scores, and observed that 20/136 tumors 
overexpressed Cav3.1; patients with alterations in Cav3.1 also showed a tendency towards shorter overall 
survival, even if devoid of statistical significance  (Fig. 1A). We then analyzed the expression of Cav3.1, Cav3.2 
and Cav3.3 mRNAs in established human GBM cell lines (U87-MG, U251-MG and A172). We found that all GBM 
cell lines expressed Cav3.1 transcripts, whereas only A172 cells expressed detectable levels of Cav3.2 transcripts 
(Fig. 1B). Cav3.3 transcripts were undetectable. 
 
TTCC blockers and gene silencing induces GBM cell death by apoptosis.   
We sought to study the impact of recognized TTCC blockers, tetralol derivatives mibefradil and NNC-55-0396, on 
the viability of A172 and U87-MG cells in our experimental setting. Both tetralols applied at 10 µM reduced 
GBM cell viability by approximately 50% after 24h of treatment (Fig. 2A and 2B), measured by the WST-1 cell 
viability and proliferation assay. Furthermore, clonogenic assays showed the absence of cell colonies after 
treatment with 10 µM mibefradil or NNC-55-0396 for a period of two weeks (Fig. 2C).  
Considering its higher selectivity for TTCC, for the rest of our studies we used NNC-55-0396 in A172 cells that 
express both Cav3.1 and Cav3.2. We performed annexin V/propidium iodide (PI) assays to estimate the induction 
of apoptosis following 24h of treatment with NNC-55-0396. The results showed a reduction of approximately 
40% in the number of live cells, together with significant increases in early and late apoptosis upon cell 
treatment with the blocker compared to untreated cells (Fig. 2D).  
We next set up to evaluate the consequences of selective TTCC gene silencing in GBM cells to discriminate the 
involvement of Cav3.1 or Cav3.2 in the apoptotic process. We tested two specific lentiviral-driven shRNAs for 
Cav3.1 and Cav3.2 (shRNAsCav3.1#1 and #2, and shRNAsCav3.2#1 and #2, respectively). shRNACav3.1#1 
efficiently knocked down Cav3.1 expression (by approximately 60-80% in U87-MG and A172 cell lines, Fig. 3A), 
whereas shRNACav3.1#2 was less efficient, with a reduction of ~30% in Cav3.1 expression in A172 cells (Suppl. 
Fig. 1A). On the other hand, shRNACav3.2#1 and #2 similarly reduced Cav3.2 expression to 30-40% in A172 cells 
(Fig 3A and Suppl. Fig. 1A).  
Cav3.1 silencing resulted in cell death. To monitor this effect, we performed annexin V/PI assays using lentiviral-
driven shRNACav3.1 or Cav3.2 silenced cells after 6 days of infection in A172 and U87-MG cell lines. As illustrated 
by phase contrast micrographs (Fig. 3B), at 6 days of infection the number of live cells was reduced by 60-70% in 
cells expressing shRNACav3.1#1 compared to control (shRNA scrambled) cells, with concomitant increases in 
early and late apoptosis (Fig. 3C). shRNACav3.1#2 produced similar results (Suppl. Fig. 1B). Silencing Cav3.2 by 
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shRNACav3.2#1 and #2 also promoted A172 cell death but to a lesser extent (Fig. 3C and Suppl. Fig 1B), with a 
decrease of about 30% in the number of live cells and increased early apoptosis (Fig. 3C and Suppl. Fig. 1B). Of 
note, cell death appeared abruptly from day 5 of infection in GBM cell lines (Suppl. Fig. 2). These results show 
the involvement of Cav3.1 and Cav3.2 in promoting GBM cell survival.    
In addition to adherent GBM cultures, we grew neurospheres (NS) derived from U87-MG. Increased expression 
of the CD133 stem cell marker in NS vs. adherent cultures was confirmed, as expected (Suppl. Fig. 3A). Next, we 
studied TTCC expression and the effects of silencing Cav3.1 in NS. Expression analysis of Cav3.1 indicated that the 
expression of this isoform was similar in NS and adherent cultures (Suppl. Fig. 3B). Of note, Cav3.2 remained 
undetectable in U87-MG NS, as previously observed in the respective adherent cell line. Interestingly, we 
confirmed the cell death induced by silencing Cav3.1 in U87-MG NS (Suppl. Fig. 3C). These results highlight the 
role of this channel in the viability of GBM adherent and stem cell-like cultures.         
 
TMZ-resistant GBM cells upregulate both TTCC and autophagy 
Having established that TTCC play a central position in the regulation of  GBM cell survival and given the resilient 
nature of GBM, we aimed at analyzing TTCC expression in recurrent GBM. We obtained paired samples of 
primary and recurrent GBM from 4 patients. Cav3.1 transcripts were overexpressed in the 3 recurrent tumors 
compared to their respective primary tumors (Fig. 4A). In contrast, only one recurrence showed overexpression 
of Cav3.2, while the rest displayed a reduced expression of Cav3.2 compared to the respective primary tumor 
(Fig. 4A). These findings prompted us to set up an in vitro cellular model of TMZ chemoresistant GBM, in which 
to investigate the effects of TTCC manipulation.   
TMZ-resistant GBM cells were generated from the A172 cell line by exposure to increasing concentrations of 
TMZ over a period of several weeks. Two clones were expanded at a concentration of 200 µM TMZ (RC1 and 
RC2). TMZ 200 µM severely impaired clonogenic growth of A172 cells (Fig. 4B). In contrast, the capacity of RC2 
cells to proliferate in colonies was unaffected by the presence of TMZ (Fig. 4B). The proliferation rate of 
resistant cells was similar to that of the parental cell line (Suppl. Fig. 4A). Next, we analyzed TTCC expression in 
resistant cells. Both RC1 and RC2 cells showed a 4 and 9-fold increase in Cav3.1 transcripts, respectively, 
compared to the parental A172 cells (Fig. 4C). Expression of Cav3.2 did not significantly increase in RC1 or RC2 
compared to A172 cells (Fig. 4C). Karyotype analysis of A172, RC1 and RC2 cells indicated that the cell lines are 
hyperpolyploid with complex chromosome formulas (Suppl. Fig. 4B-C). No specific chromosomal alterations 
could be correlated with the resistance to TMZ by conventional cytogenetic studies. Together, the expression of 
Cav3.1 is upregulated in TMZ-resistant GBM cells and in a fraction of recurrent GBM samples, pointing to a 
possible involvement of these channels in chemoresistance.    
Acute application of TMZ is a known inducer of autophagy in GBM cells through activation of the ATM/AMP-
activated protein kinase (AMPK)/mTOR pathway (30)(31)(32). In addition, we had previously found that the 
expression of the Cav3.1 isoform and autophagy markers positively correlates in melanoma cells (33)(24). 
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Therefore, we studied whether RC2 or A172 cells treated with TMZ in acute (6h) or chronic (72h) treatments 
display an altered autophagic flux compared to untreated A172 cells. TMZ-treated A172 and RC2 cells showed 
increased P-AMPK levels, compared to control cells (Fig. 5A). Moreover, the levels of autophagy-related protein 
BECLIN1 increased in parallel with ATG5 monomers and ATG5-ATG12 dimers following exposure to TMZ, and in 
RC2 cells. Levels of SQSTM1/P62, a cargo chaperone/receptor of autophagosomes, may reflect simultaneous 
gene upregulation and protein degradation in a situation of enhanced autophagy (34). Despite SQSTM1/P62 
protein levels did not show consistent changes upon TMZ treatment, we found a 2-fold increase of SQSTM1/P62 
mRNA levels in RC2 (compared to parental A172 cells; Fig. 5B), consistent with an increased autophagosome 
biogenesis. Finally, we studied the autophagic flux using the ptfLC3A construct (26) and compared RC2 cells to 
A172 cells. Treatment with the autophagy inducer rapamycin, or blocker chloroquine was also performed as 
control. In this assay red puncta represent autolysosomes, whereas yellow (red and green) puncta are indicative 
of autophagosomes. Quantification of puncta demonstrated that RC2 shows a significant increase in the number 
of red puncta vs. green puncta, similar to the effect of rapamycin in A172 cells. In contrast, A172 cells treated 
with chloroquine showed a balance between green and red puncta (yellow dots), as expected (Fig. 5C). 
Together, these results confirm that TMZ-chemoresistant RC2 cells display an enhanced autophagic flux in 
addition to the upregulation of Cav3.1.              
To address the involvement of Cav3.1 in the survival of RC2 cells, we silenced the expression of this channel in 
RC2 cells and then performed Annexin V/PI staining. Results showed a reduction of 46% in the number of live 
cells upon silencing Cav3.1 in RC2 cells (using shRNACav3.1#1), a 13% increase of cells in early apoptosis and a 22 
% increase of cells in late apoptosis (Fig. 5D), similar to results in the A172 cell line (Fig. 3C). RC2 cells were also 
sensitive to the TTCC blocker NNC-55-0396 (10 µM, 24h), which reduced cell viability by 72% (Fig. 5E).  
 
Cav3.1 channels play a pro-autophagic function  
Previous studies and our results in RC2 cells suggested a pro-autophagic function of Cav3.1. We further analyzed 
key components of the autophagy pathway, autophagy-related protein LC3-II, P62 and ubiquitination of 
proteins (cargo). Surprisingly, P62 levels dropped upon silencing Cav3.1 in GBM cells. Interestingly, this decrease 
in P62 was linked to increased levels of LC3-II and of ubiquitinated proteins, compared to control cells (Fig. 6A). 
These findings are compatible with a defective autophagy, possibly caused by the lack of the cargo receptor P62. 
In addition to changes in P62 protein levels, silencing Cav3.1 significantly reduced P62 mRNA levels in A172 cells 
(Fig. 6B). Bioinformatics analysis using the Gliovis platform confirmed a positive relationship between Cav3.1 and 
P62 or LC3A in GBM samples (Fig. 6C). These findings suggest that Cav3.1 signaling positively regulates 
autophagy through the transcriptional regulation of P62.  
The association between Cav3.1 and autophagic markers was additionally explored in GBM biopsies included in a 
tissue microarray (TMA). Immunostaining results indicated that the expression of Cav3.1 positively correlates 
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with that of P62 and LC3 in tumor samples (Pearson correlation coefficient (pcc) = 0.67, p = 7.15 E-05 for p62; 
pcc = 0.42, p=0.0017 for LC3) (Fig. 6D-E and Suppl. Fig. 5).    
 
Silencing Cav3.1 expression reduces GBM growth in vivo 
In light of the observed effects on GBM cell viability and the deregulation of autophagy upon silencing Cav3.1 
expression, we performed xenograft experiments to evaluate the effect of depleting Cav3.1 in tumor 
development. We used U87-MG cells, a cell line that expresses only detectable levels of Cav3.1. We generated 
tumors using either control (scrambled shRNA) cells or cells expressing a shRNA against Cav3.1 (shRNACav3.1#1 
and measured tumor size from day 2 up to 15 days. Growth was stopped in tumors formed by U87-MG cells 
depleted of Cav3.1 compared to control tumors (Fig. 7A). We analyzed proliferation markers (Ki67 and CyclinD1) 
and the autophagic protein P62 in tumor sections. We observed a reduction of ~30%  in the number of cells 
immunostained for both proliferative markers in the tumors formed by cells expressing the shRNA against 
Cav3.1, compared to controls (Fig. 7B). In addition, in agreement with in vitro results, we observed a significant 
reduction of the immunostaining for P62 in tumors derived from cells depleted of Cav3.1 (Fig. 7B).  
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DISCUSSION    
In the present work we show that Cav3.1 and Cav3.2 isoforms of TTCC are expressed in GBM cell lines, being 
Cav3.1 prevalent at the transcript level. This is in syntony with previous reports from GBM (23)(35)(36)(37), but 
against findings in other cancer types, in which overexpression of Cav3.2 is common (8). Although Cav3.2 is 
reportedly downregulated in human GBM samples (38), recently Zhang et al. described that Cav3.2 was highly 
expressed in a subset of GBM tumors and in GSC, and that patients with alterations in the Cav3.2 gene (involving 
its upregulation) presented a trend towards shorter survival in Kaplan-Meier estimates (20). Furthermore, 
pharmacological blockade of TTCC with mibefradil reduced stemness and the viability of GSC, by inhibiting 
prosurvival pathways while stimulating proapoptotic factors. In addition, oral administration of mibefradil 
inhibited the growth of GSC-derived GBM murine xenografts, prolonged host survival and sensitized tumors to 
TMZ treatment, leading to the claim that Cav3.2 blockade was underlying these effects. However, the authors 
did not analyze the expression of Cav3.1 demonstrated in GSC (22). Indeed, our results with U87-MG NS cultures 
show that stemness neither altered the expression of Cav3.1 nor promoted the expression of Cav3.2 to the 
threshold of detection by qPCR. Furthermore, the viability of the NS cells was still compromised by Cav3.1 
knockdown. In addition, we analyzed the TGCA database under the same astringency z-scores as in (20), and 
observed that 20/136 tumors presented alterations in the Cav3.1 gene involving its upregulation, which also 
associated to a worse outcome. Nevertheless, in our experimental setting A172 cells additionally expressed 
Cav3.2 channels and were sensitive to both Cav3.1 and Cav3.2 gene knockdown. Hence, it can be concluded that 
both TTCC isoforms play a role in GBM biology.  
TTCC pharmacological blockers have shown both to halt cell proliferation and induce apoptosis in different 
cancer types and, specifically, in GBM cells in vitro. However, neither currently available blockers are able to 
discriminate between TTCC isoforms, nor are devoid of off-target effects at cytotoxic concentrations (Visa et al., 
submitted). Accurate target identification is paramount, because of a differential role for Cav3.1 and Cav3.2 
isoforms demonstrated in different cell systems through (over)expression or gene silencing experiments. For 
instance, although both isoforms have been involved in cell cycle progression and survival, only the expression 
of Cav3.1 shows a positive correlation with autophagic markers in melanoma (24). In contrast Cav3.2, whose 
expression increases in hypoxic conditions, has been implied in cell growth, stemness and cancer metastasis (8). 
Specific gene silencing with lentiviral-driven shRNAs indicated that, in those GBM cell lines in which both TTCC 
were expressed, silencing of either one induced significant cell death measured in viability and annexin assays, 
principally by apoptosis. Noticeably, the induction of apoptosis measured at the same time points was higher for 
Cav3.1 knockdown than for Cav3.2 knockdown.  
In line with a differential role, we also describe the upregulation of Cav3.1 channels in a TMZ-chemoresistant cell 
line. Although paired biopsies of primary and recurrent GBM from the same patient are scarce, results from 4 
paired samples are also suggestive of a preferential upregulation of Cav3.1 in recurrent GBMs. It has been 
established that TMZ-dependent DNA damage activates AMPK, thus enhancing autophagy as a response to 
16 
 
therapy (30)(39)(40). Consistently, combined applications of TMZ and autophagy inhibitors synergistically 
increase GBM cytotoxicity (41)(42)(43)(44). Here we found that TMZ-resistant cells upregulate autophagy in 
parallel to the overexpression of Cav3.1, advocating for the use of TTCC blockers in recurrent GBM.  
One important goal of this work was to confirm a relationship between expression of Cav3.1 and autophagy, 
identified previously in melanoma cells, by means of gene knockdown in GBM. Indeed, Cav3.1 gene silencing 
deregulated autophagy, involving reduction of P62/SQSTM1 at the transcriptional level and accumulation of 
ubiquitinated proteins. Further evidence of the Cav3.1-autophagy association came from the GBM TMA study, 
displaying positive correlations between Cav3.1 and LC3/P62. In addition, murine U87-MG xenograft 
experiments indicated that Cav3.1 plays a role in GBM growth in vivo, such that Cav3.1 silencing reduced tumor 
size, concomitant with reductions of proliferation markers (Ki67 and CyclinD1), and of P62. In a similar xenograft 
model, NNC-55-0396 significantly suppressed GBM tumor growth (19). GBM cell-line xenografts show good 
engraftment and growth rates, but whether they reflect the biological nature of GBM is unclear (45). Yet,  the 
involvement of Cav3.1 in autophagy regulation warrants its investigation as a chemotherapeutic target 
particularly in recurrent, TMZ-resistant GBM, because these tumors display higher levels of both Cav3.1 and 
autophagy markers compared to primary GBM.  
In conclusion, in the present work we provide in vitro and in vivo evidence for a role of the Cav3.1 isoform of 
TTCC in GBM proliferation, survival and autophagy, emphasizing its involvement in recurrent GBM, in which it 
may provide a pathway for chemotherapeutic resistance.  
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Figure legends 
Figure 1. Prevalence of Cav3.1 in GBM cell lines.  A) Overall Survival Kaplan-Meier estimates for patients with 
GBM presenting alterations in CACNA1G  gene. Analysis was obtained from TGCA data set for Cav3.1 (CACNA1G) 
and Cav3.2 (CACNA1H) mRNA expression. Out of 136 GBM samples, 20 cases overexpressed Cav3.1 (15 %), 13 
cases overexpressed Cav3.2 (10 %) and 5 cases (4 %) overexpressed both channels, being the co-ocurrence 
significant (p < 0.05). mRNA expression was quantified using the RNASeq V2 RSEM platform, with a z-score 
threshold set at ± 1.0. Patients with alterations (overexpression) in Cav3.1 presented a trend towards shorter 
overall survival, although there were no stastistical differences between the two groups (p=0.216). B) Cav3.1 and 
Cav3.2 mRNA levels as detected by real-time PCR from A172, U251-MG and U87-MG GBM cell lines. Cav3.1 is 
prevalent, while Cav3.2 was only detected in the A172 cell line. **, p<0.01 and ***, p<0.001.  
 
Figure 2. TTCC blockers decrease GBM cell viability and promote apoptosis.  A-B) WST-1 cell viability assays 
performed using A172 (A and B) or U87-MG cells (B) untreated or treated with Mibefradil or NNC-55-0396 ( as 
indicated) for 24h. C) Representative images from clonogenic assays performed on A172 cells untreated or 
treated with Mibefradil or NNC-55-0396 (as indicated) for 12-15 days. Both blockers significantly reduced cell 
viability and colony growth at 10 µM. D) Annexin V/PI staining experiments show that NNC-55-0396 10 µM (24h) 
significantly reduced the number of live cells and promoted apoptosis of A172 cells compared to untreated 
control cells (*, p<0.05; **, p<0.01; ***, p<0.001).  
 
Figure 3.  Silencing of Cav3.1 by shRNA, and to a lesser extent silencing of Cav3.2, induces GBM cell death. A) 
shRNAs Cav3.1#1 (left) and Cav3.2#1 (right) significantly reduce Cav3.1 and Cav3.2 mRNA levels, respectively, in 
GBM cell lines (U87-MG and A172) compared to scrambled shRNA, at day 4 after lentiviral infection. B-C) Phase 
contrast micrographs (B) and Annexin V/PI staining experiments (C) indicate that silencing Cav3.1 expression 
(using shRNACav3.1#1) and, to a lesser extent silencing Cav3.2 (shRNACav3.2#1), induces apoptosis compared to 
controls (shRNA scrambled, Scr) in A172 and U87-MG cell lines. Annexin V/PI experiments were performed after 
6 days of infection. Bar=200 µm (*, p<0.05; **, p<0.01; ***, p<0.001).  
 
Figure 4. Recurrent/chemoresistant GBM overexpresses Cav3.1. A) mRNAs were purified from primary and 
recurrent GBM biopsies obtained from the same patient, retrotranscribed to cDNA and Cav3.1 and Cav3.2 
transcripts analyzed by real-time PCR. Analysis of paired biopsies of four patients (P1-P4) indicates that 
recurrent GBMs overexpress Cav3.1 (3 of 4 samples) and downregulate Cav3.2 (3 of 4 samples) compared to 
their respective primary tumors. Plots represent triplicates from one experiment (due to sample shortage). B) 
Representative images of clonogenic assay (top) and phase contrast micrographs (bottom) comparing A172 cells 
and the chemoresistant RC2 clone derived from the A172 cell line (grown under control conditions or upon 
exposure to 200 µM TMZ). Images illustrate the resistance of RC2 cells to TMZ. Bar=200 µm. C) Cav3.1 and 
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Cav3.2 mRNAs analysis by qPCR in TMZ-chemoresistant cultures compared to the A172 parental cell line 
indicates that the RC1 and RC2 cells upregulate Cav3.1 (*, p<0.05; **, p<0.01). 
 
Figure 5. TMZ-resistant RC2 cells display upregulated autophagy and are sensitive to TTCC blockade or silencing. 
A) (Left) P-AMPK levels increase upon TMZ treatment (6 or 72h) and in RC2 compared to the parental A172 cell 
line (the A172 control sample was loaded twice for better comparison). (Right) Beclin1/BECN1 expression, ATG5 
monomers (35 kDa) and the ATG5-ATG12 (54 kDa) dimers increased upon TMZ treatment and in RC2 cells 
compared to A172 cells. β-actin/ACTB was used as a loading control. B) P62 transcripts are upregulated in RC2 
compared to the parental A172 cell line. C) A172 cells transfected with the ptfLC3 plasmid were treated for 24h 
with 25 µM chloroquine or 500 nM rapamycin as controls for autophagy blockade and autophagic flux induction, 
respectively. RC2 cells were compared to untreated A172 cells. RC2 displayed abundant red puncta indicating 
increased autophagic flux in basal conditions. Bar=10 µm. Plot represents the average number of red and green 
puncta per cell. A172 cells treated with chloroquine display similar numbers of red and green (yellow) puncta. 
RC2 cells, similar to A172 cells treated with rapamycin, show increased numbers of red dots. D) Annexin V/PI 
staining experiments indicate that silencing Cav3.1 (shRNACav3.1#1) induces apoptosis of RC2 cells and 
decreases the number of live cells compared to control cells (shRNA scrambled, Scr). E) WST-1 cell viability 
assays performed using A172 or RC2 cells untreated (control, C) or treated with NNC-55-0396 (24h at the 
indicated concentration) show an increased sensitivity of RC2 cells to the TTCC blocker compared to A172 cells 
(*, p<0.05; **, p<0.01; ***, p<0.001). 
 
Figure 6.  Cav3.1 regulates autophagy. A) A172 cells expressing  shRNACav3.1#1, shRNACav3.2#1 or scrambled 
(scr) were analyzed for P62, LC3 or ubiquitinated proteins. Silencing Cav3.1 resulted in decreased P62 and 
increased LC3-II levels, accompanied by increased ubiquitinated proteins, consistent with a defective autophagy. 
Note that bafilomycin (baf) treatment increased the levels of ubiquitinated proteins by blocking autophagic flux. 
β-actin was used as a loading control. B) P62 mRNA levels decreased upon silencing Cav3.1 in A172 cells (***, 
p<0.001). C) Positive correlations between Cav3.1/CACNA1G and P62/SQSTM1 (top) or Cav3.1/CACNA1G and 
LC3A/MAP1LC3A (bottom) mRNA expression as obtained from the Gliovis platform using the Rembrandt dataset 
(pcc for P62=0.206, p<0.01 **) ; pcc for LC3A=0.46; **). D) Representative examples of two GBM cases analyzed 
in a TMA following immunostaining for Cav3.1, P62 and LC3. E) Positive correlations between the histocores 
obtained from the 57 GBM samples included in the TMA for Cav3.1 and P62 (pcc=0.67), or Cav3.1 and LC3 
(pcc=0.42), which were significant according to Pearson’s test (see p values). Bar=50 µm.    
 
Figure 7. Silencing Cav3.1 reduces tumor growth. A) Left, graph of tumor growth over time of SCID mice 
xenografts formed by U87-MG cells (control or Cav3.1-silenced) calculated vs. the tumor size at day 2 of tumor 
induction. Right, representative pictures of a mouse xenografted with control (scr shRNA) or Cav3.1 silenced 
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U87-MG cells (shRNACav3.1#1) at either flank. Tumors were allowed to grow for 13 days. Representative 
examples of tumors from each condition are shown. (B) Tumors were collected and prepared for 
immunostaining. Immunostainings against Ki67, CyclinD1 and P62 from tumors expressing scrambled shRNA or 
shRNACav3.1#1. U87-MG tumors depleted of Cav3.1 showed decreased immunostaining of proliferative 
markers, Ki67 (72.7 ± 6.7 %) and CyclinD1 (68.3 ± 13.5 %), and of P62 (29.0 ± 12.3 %). Bars= 100 μm. 
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